Rationale for Therapeutic Use of Lipid Transport Mediators in Renal Disease

Local TNF causes NFATc1-dependent cholesterol-mediated podocyte injury.

Systemic and renal lipids in kidney disease development and progression 

Metabolism, energetics, and lipid biology in the podocyte - cellular cholesterol-mediated glomerular injury.

Lipid biology of the podocyte--new perspectives offer new opportunities.

Renal lipid metabolism and lipotoxicity. 

Cholesterol Efflux MediatorTM VAR 200 and Renal Disease

Cyclodextrin Protects Podocytes in Focal Segmental Glomerulosclerosis (FSGS)

Hydroxypropyl-β-cyclodextrin protects from kidney disease in experimental Alport syndrome and focal segmental glomerulosclerosis.

Cyclodextrin improves renal function in experimental alport syndrome.

Cyclodextrin protects podocytes in diabetic kidney disease.